OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 29, 2020
NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.
October 27, 2020
The Phase III clinical trial of NVX-CoV2373 is expected to be fully enrolled in the UK and will begin in the US and Mexico by the end of November 2020.
October 23, 2020
Gilead’s antiviral drug Veklury is the first approved treatment in the US for COVID-19.
October 21, 2020
Subsequent guidance and manufacturing realities make portions of USP Chapters and significantly less relevant. The authors suggest formal chapter revisions.
Joerg Ahlgrimm has left Lonza and is now leading The Discovery Labs’ mission to establish a powerhouse for cell and gene therapy development and manufacturing in the Philadelphia area.
October 20, 2020
Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.
The company’s new closed cell therapy processing system enables scalable, cost-effective development and manufacturing of cell therapies.
The company was selected because of its nucleic acid platform which, when combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system.
Branching out from roots in industrial biotechnology, Riffyn Data Systems (and its CEO Tim Gardner) is taking the message of data-driven process improvement to biopharma.
October 16, 2020
The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.